References
- Dron JS Wang J Low-Kam C Polygenic determinants in extremes of high-density lipoprotein cholesterol J Lipid Res 2017 Nov 58 11 2162 70
- Madsen CM Varbo A Nordestgaard BG Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies Eur Heart J 2017 Aug 21 38 32 2478 86
- Hirata A Sugiyama D Watanabe M .; EPOCH-JAPAN Research Group Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study J Clin Lipidol. 2018 May - Jun 12 3 674 84.e5
- Wilkins JT Ning H Stone NJ Coronary heart disease risks associated with high levels of HDL cholesterol J Am Heart Assoc 2014 Mar 13 3 2 e000519
- Ahmed HM Miller M Nasir K Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis Am J Epidemiol 2016 May 15 183 10 875 83
- Schwartz GG Olsson AG Abt M .; dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 2012 Nov 29 367 22 2089 99
- Barter PJ Caulfield M Eriksson M Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 2007 Nov 22 357 21 2109 22
- Lincoff AM Nicholls SJ Riesmeyer JS .; ACCELERATE Investigators Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease N Engl J Med 2017 May 18 376 20 1933 42
- Bowman L Hopewell JC Chen F .; HPS3/TIMI55–REVEAL Collaborative Group Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease N Engl J Med 2017 Sep 28 377 13 1217 27
- Ference BA Kastelein JJP Ginsberg HN Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk JAMA 2017 Sep 12 318 10 947 56
- Rosenson RS Davidson MH Le NA Burkle J Pourfarzib R Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy Cardiovasc Drugs Ther 2015 Feb 29 1 41 50
- Mora S Glynn RJ Ridker PM High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy Circulation 2013 Sep 10 128 11 1189 97
-
Mackey
RH
Greenland
P
Goff
DC
Jr Lloyd-Jones D Sibley CT Mora S High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis) J Am Coll Cardiol 2012 Aug 7 60 6 508 16 - Khera AV Demler OV Adelman SJ Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) Circulation 2017 Jun 20 135 25 2494 504
- Khine HW Teiber JF Haley RW Khera A Ayers CR Rohatgi A Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study Atherosclerosis 2017 Aug 263 156 62
- Mani P Ren HY Neeland IJ The association between HDL particle concentration and incident metabolic syndrome in the multi-ethnic Dallas Heart Study Diabetes Metab Syndr 2017 Nov 11 Suppl 1 S175 S179
- Khera AV Cuchel M de la Llera-Moya M Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 2011 Jan 13 364 2 127 35
- Rohatgi A High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity Prog Cardiovasc Dis 2015 Jul–Aug 58 1 32 40
- Rohatgi A Khera A Berry JD HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 2014 Dec 18 371 25 2383 93
- Hernáez Á Castañer O Elosua R Mediterranean Diet Improves High-Density Lipoprotein Function in High-Cardiovascular-Risk Individuals: A Randomized Controlled Trial Circulation 2017 Feb 14 135 7 633 43
- Brassard D Arsenault BJ Boyer M Saturated Fats from Butter but Not from Cheese Increase HDL-Mediated Cholesterol Efflux Capacity from J774 Macrophages in Men and Women with Abdominal Obesity J Nutr 2018 Apr 1 148 4 573 80
- Andersen CJ Blesso CN Lee J Egg consumption modulates HDL lipid composition and increases the cholesterol-accepting capacity of serum in metabolic syndrome Lipids 2013 Jun 48 6 557 67
- Sarzynski MA Ruiz-Ramie JJ Barber JL Effects of Increasing Exercise Intensity and Dose on Multiple Measures of HDL (High-Density Lipoprotein) Function Arterioscler Thromb Vasc Biol 2018 Apr 38 4 943 52
- Boyer M Mitchell PL Poirier DP Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia Am J Physiol Endocrinol Metab 2018 Oct 1 315 4 E460 E468
- Aicher BO Haser EK Freeman LA Diet-induced weight loss in over-weight or obese women and changes in high-density lipoprotein levels and function Obesity (Silver Spring) 2012 Oct 20 10 2057 62
- Albaghdadi MS Wang Z Gao Y Mutharasan RK Wilkins J High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacity Are Not Affected by Supervised Exercise but Are Associated with Baseline Interleukin-6 in Patients with Peripheral Artery Disease Front Cardiovasc Med 2017 Mar 2 4 9
- Koba S Ayaori M Uto-Kondo H Beneficial Effects of Exercise-Based Cardiac Rehabilitation on High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity in Patients with Acute Coronary Syndrome J Atheroscler Thromb 2016 Jul 1 23 7 865 77
- van Capelleveen JC Kastelein JJ Zwinderman AH Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses J Clin Lipidol 2016 Sep–Oct 10 5 1137 1144.e3
- Nicholls SJ Ruotolo G Brewer HB Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib J Am Coll Cardiol 2015 Nov 17 66 20 2201 10
- Tardif JC Rhainds D Brodeur M Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes Circ Cardiovasc Genet 2016 Aug 9 4 340 8
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE); 2018 Sep 26 [cited 2018 Oct 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02525939
- Quinn AG Schwemberger R Stock EO Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients J Clin Lipidol. 2017 Jul - Aug 11 4 908 14
- Nenseter MS Narverud I Graesdal A Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis J Clin Lipidol 2013 Mar–Apr 7 2 109 16
- Adorni MP Zimetti F Puntoni M Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis J Lipid Res 2012 May 53 5 984 9
- Lappegård KT Kjellmo CA Ljunggren S Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study Transfus Apher Sci 2018 Feb 57 1 91 6
- Orsoni A Villard EF Bruckert E Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia J Lipid Res 2012 Apr 53 4 767 75
- Nissen SE Tsunoda T Tuzcu EM Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 2003 Nov 5 290 17 2292 300
- Nicholls SJ Puri R Ballantyne CM Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial JAMA Cardiol. 2018 Jul 25
- Nicholls SJ Andrews J Kastelein JJP Effect of Serial Infusions of CER-001, a Pre-beta High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial JAMA Cardiol. 2018 Jul 25
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (TANGO); 2017 Mar 20 [cited 2018 Oct 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02697136
- Michael Gibson C Korjian S Tricoci P Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I) Circulation 2016 Dec 13 134 24 1918 30
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II); 2018 Mar 22 [cited 2018 Oct 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT0347322
DOI: https://doi.org/10.14797/mdcj-15-1-39 | Journal eISSN: 1947-6108
Language: English
Page range: 39 - 46
Published on: Jan 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Kayla A. Riggs, Anand Rohatgi, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.